Henry Schein, Inc. (HSIC) Receives “Hold” Rating from Jefferies Group LLC
A number of other brokerages have also commented on HSIC. Piper Jaffray Companies began coverage on Henry Schein in a research report on Monday, June 12th. They set a neutral rating and a $200.00 price objective for the company. Zacks Investment Research lowered Henry Schein from a buy rating to a hold rating in a research report on Friday, June 23rd. Credit Suisse Group AG restated a hold rating and set a $160.00 price objective on shares of Henry Schein in a research report on Thursday, July 13th. Stifel Nicolaus restated a hold rating on shares of Henry Schein in a research report on Thursday, July 6th. Finally, Barrington Research raised their price objective on Henry Schein from $196.00 to $198.00 and gave the stock an outperform rating in a research report on Wednesday, May 10th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Henry Schein presently has an average rating of Hold and a consensus price target of $183.40.
Henry Schein (NASDAQ:HSIC) traded up 0.26% on Friday, hitting $184.92. 273,667 shares of the stock were exchanged. The company’s 50-day moving average is $183.79 and its 200-day moving average is $172.80. The company has a market cap of $14.67 billion, a PE ratio of 28.10 and a beta of 1.09. Henry Schein has a 52 week low of $146.23 and a 52 week high of $186.99.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $1.76 EPS for the quarter, topping the Zacks’ consensus estimate of $1.65 by $0.11. Henry Schein had a return on equity of 19.74% and a net margin of 4.53%. The firm had revenue of $2.92 billion during the quarter, compared to analyst estimates of $2.83 billion. During the same period last year, the company posted $1.41 EPS. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. On average, analysts predict that Henry Schein will post $7.28 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/07/22/henry-schein-inc-hsic-receives-hold-rating-from-jefferies-group-llc.html.
In other news, EVP Gerald A. Benjamin sold 12,578 shares of Henry Schein stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $175.10, for a total transaction of $2,202,407.80. Following the completion of the sale, the executive vice president now directly owns 44,061 shares in the company, valued at approximately $7,715,081.10. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.27% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the stock. SpiderRock Advisors LLC purchased a new stake in shares of Henry Schein during the first quarter valued at about $102,000. Westside Investment Management Inc. purchased a new stake in shares of Henry Schein during the first quarter valued at about $168,000. JNBA Financial Advisors purchased a new stake in shares of Henry Schein during the first quarter valued at about $170,000. Peddock Capital Advisors LLC raised its stake in shares of Henry Schein by 29.1% in the first quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock valued at $186,000 after buying an additional 247 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Henry Schein by 5.7% in the first quarter. Van ECK Associates Corp now owns 1,138 shares of the company’s stock valued at $193,000 after buying an additional 61 shares in the last quarter. Institutional investors and hedge funds own 90.74% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.